Prevalence and correlates of restless legs syndrome in men living with HIV.

BACKGROUND: Data on the prevalence and correlates of restless legs syndrome (RLS) in people with HIV are limited. This study sought to determine the prevalence of RLS, associated clinical correlates, and characterize sleep-related differences in men with and without HIV.
METHODS: Sleep-related data were collected in men who have sex with men participating in the Multicenter AIDS Cohort Study (MACS). Demographic, health behaviors, HIV status, comorbidities, and serological data were obtained from the MACS visit coinciding with sleep assessments. Participants completed questionnaires, home polysomnography, and wrist actigraphy. RLS status was determined with the Cambridge-Hopkins RLS questionnaire. RLS prevalence was compared in men with and without HIV. Multinomial logistic regression was used to examine correlates of RLS among all participants and men with HIV alone. Sleep-related differences were examined in men with and without HIV by RLS status.
RESULTS: The sample consisted of 942 men (56% HIV+; mean age 57 years; 69% white). The prevalence of definite RLS was comparable in men with and without HIV (9.1% vs 8.7%). In multinomial regression, HIV status was not associated with RLS prevalence. However, white race, anemia, depression, and antidepressant use were each independently associated with RLS. HIV disease duration was also associated with RLS. Men with HIV and RLS reported poorer sleep quality, greater sleepiness, and had worse objective sleep efficiency/fragmentation than men without HIV/RLS.
CONCLUSIONS: The prevalence of RLS in men with and without HIV was similar. Screening for RLS may be considered among people with HIV with insomnia and with long-standing disease.

Introduction

Restless legs syndrome (RLS) or Willis-Ekbom disease is a neurological disorder which interferes with rest and sleep, leading to impaired daytime functioning and decreased quality of life [1]. The cardinal symptoms consist of an irresistible urge to move the limbs, occurring after periods of inactivity, worsening at night, that improve with moving the extremities [2]. Symptoms of RLS can prevent people from falling asleep [3]. In addition, up to 90% of people with RLS may also experience periodic limb movements of sleep (PLMS), which are repetitive flexion movements of the toe, ankle, and hip that can further fragment sleep [1, 4]. Among the US general population, the prevalence of RLS ranges between 2.5–16.0% with a higher prevalence in women, older adults, and those of northern European descent [5-7]. In addition, chronic conditions such as iron deficiency anemia, type 2 diabetes, chronic kidney disease, and major depression have been associated with RLS [8, 9].

Data are sparse about the prevalence or predictors of RLS in people living with human immunodeficiency virus (HIV). To date, only three studies exist examining the prevalence of RLS in people living with HIV (PLHIV) and have been equivocal regarding the independent influence of HIV infection on RLS prevalence [10-12]. Use of clinic-based samples, varying definitions of RLS, limited sample sizes, and lack of assessment of other medical comorbidities (e.g., chronic kidney disease, diabetes) and lifestyle factors (e.g., illicit drug use) are likely contributors to the incongruent findings across available studies [10-12]. Furthermore, there are no data on objective sleep correlates of RLS symptoms in PLHIV derived either from actigraphy or polysomnography. Given that comorbid sleep disorders, such as sleep-disordered breathing and habitually short sleep duration can worsen RLS symptoms, characterizing and accounting for such disorders would allow for an assessment as to whether HIV infection is an independent contributor [13, 14]. Thus, a more comprehensive understanding of the prevalence and determinants of RLS in PLHIV may help determine the burden of disease and potentially customize future intervention studies.

To address such limitations, recently collected data on sleep in the Multicenter AIDS Cohort Study (MACS) were leveraged along with the comprehensive battery of measures related to HIV, lifestyle, and medication use to define the prevalence and correlates of RLS in a large, ethnically and racially diverse community-based sample. The aims of this study were to determine the prevalence of RLS in men with and without HIV, examine if viral load, CD4 count, and HIV disease duration are associated with the prevalence and severity of RLS, and assess the level of subjective and objective sleep-related impairment in men with HIV and RLS compared to men without RLS.

Methods

Participants

The study sample consisted of 942 men with and without HIV participating in an ancillary sleep protocol of the Multicenter Aids Cohort Study (MACS). Briefly, the MACS is a longitudinal cohort study (1984–2019) of HIV, its treatment trajectories, and associated comorbidities in men who have sex with men [15]. The cohort includes those with HIV and those at risk for HIV. Study participants complete various psychosocial/behavioral questionnaires, and laboratory and physical exam assessments every six months. The demographic, anthropometric, health behaviors, HIV status/disease severity, medical comorbidities and medication variables used for this analysis come from the parent study visits coinciding with the sleep assessments. Participants for the ancillary sleep protocol were recruited from four US sites (Baltimore, Chicago, Pittsburgh, Los Angeles) from April 2018 to September 2019. Study participants who agreed to participate were asked to complete sleep questionnaires and objective sleep testing as described below. To be included in this analysis, participants had to complete the sleep questionnaires, overnight polysomnography, and actigraphy. Participants were excluded if the RLS questionnaire was not completed or the sleep recordings were of poor quality that would have precluded sleep staging or scoring of disordered breathing events. The Investigational Review Board at Johns Hopkins University approved the protocol (IRB00219740) and all participants signed a written informed consent prior to enrollment.

Subjective sleep measures

Symptoms of RLS were determined per the Cambridge-Hopkins restless legs syndrome questionnaire (CH-RLSq) [16]. This self-reported instrument queries not only for the diagnostic criteria of RLS but also excludes its clinical mimickers. As per instructions of this instrument’s developer, three RLS categories were generated by this questionnaire: definite RLS, no RLS, or indeterminate. These CH-RLSq generated categories are used throughout the manuscript. Items embedded in the questionnaires assess age at symptom onset, symptom frequency, and distress level associated with disease. The CH-RLSq has been found to have a sensitivity and specificity of 87% and 94%, respectively, for determining RLS from not RLS [16].

Global sleep quality was measured per the Pittsburgh sleep quality index (PSQI). Individual items assess sleep onset latency, habitual sleep times, time in bed, and sleep duration. A global PSQI score greater than five yields a diagnostic sensitivity of 89.6% and specificity of 86.5% in distinguishing good and poor sleepers [17].

Daytime sleepiness was determined using the Epworth sleepiness scale (ESS) which consists of eight items rated on a scale of 0–3 with higher scores indicating a greater propensity to fall asleep in different situations [18]. An ESS score > 10 was considered a cut off value for excessive daytime sleepiness.

Objective sleep assessments

A single night of home polysomnography was performed at the participant’s home with a type II portable sleep monitor (Nox A1 PSG; Nox Medical, Reykjavik, Iceland). Sleep parameters were measured using the recommended criteria [19]. Apnea was defined as cessation of airflow for at least 10 seconds. Hypopneas were defined as a 30% reduction in airflow for at least 10 seconds associated with either a 3% oxygen desaturation or arousal. Obstructive sleep apnea (OSA) was diagnosed if the apnea-hypopnea index (AHI) was at least 5 events/hr of sleep. Periodic limb movements were scored per standard criteria [3].

Rest-sleep patterns were assessed over seven consecutive days using actigraphy (Actiwatch Spectrum, Philips Respironics, Murrysville, PA) worn on the dominant wrist. An actigraph is a wristwatch-like device that records movement through an accelerometer and has a photodiode for detecting light intensity exposure. Activity data were collected in 30-second epochs and sleep-wake inferences were made using the Actiware automated scoring algorithm. The wake threshold value (i.e., the number of activity counts used to define wake) was set to medium sensitivity of 40.0 activity counts per epoch. Estimated sleep onset latency, total sleep time, sleep efficiency, and fragmentation index were determined.

HIV status, health behaviors, and medical comorbidities

The following markers were used as surrogates of HIV disease or treatment. HIV status was determined at study entry by a commercially available HIV test as per study protocol [15]. For men with HIV, viral load (HIV RNA copies/ml), CD4 Tcell count/ml, CD4 Tcell count nadir, and HIV disease duration were recorded. Undetectable viral load was defined as lab value of less than 20 viral copies/ml. Antiretroviral (ART) treatment and cumulative exposure history were obtained from interviewer administered assessments and historical data collected as part of the biannual visits.

Several health behaviors, comorbid conditions, and medications that have been previously reported to be associated with RLS symptoms were examined at visits coinciding with the sleep ancillary study [9]. Smoking status and heavy alcohol consumption (> 14 drinks/week) were based on self-report [20]. Similarly, daily use of marijuana/hash and illicit heroin/opiate use since last visit was also assessed. Hypertension was determined per self-report or use of antihypertensive medication. Type 2 diabetes was determined by fasting glucose ≥ 126 mg/dl, hemoglobin A1c ≥ 6.5%, or use of hypoglycemic medications. Chronic kidney disease was defined based on estimated glomerular filtration rate < 60 ml/min [21]. Anemia was diagnosed if the hemoglobin or erythropoietin value was below 5th percentile for age [22]. Current depressive symptoms were per Center for Epidemiologic Studies Depression (CESD) scale ≥ 16 [23]. Finally, use of medications known to exacerbate (i.e., antidepressants) or ameliorate (i.e., sedatives/anxiolytic/tranquilizers) RLS symptoms was obtained from the biannual visit.

Data analysis

Demographic and clinical characteristics were compared between men with and without HIV. Student’s t-test was used for continuous variables and chi-square test was used for categorical data. The unadjusted prevalence of RLS and characteristics were subsequently compared by HIV status. To examine the independent association between HIV status and prevalent RLS or indeterminate status, multivariable logistic regression models for RLS status were used to adjust for potential confounders. Based on prior research [5, 7, 9], multinomial logistic regression models were constructed containing independent variables in the following domains: sociodemographic (age, race), health behaviors (smoking status, excessive alcohol use, substance use status), and medical comorbidities (HIV, diabetes, hypertension, chronic kidney disease, depressive symptoms). To determine whether HIV-related variables were associated with RLS status, an additional multinomial model was constructed sequentially adjusting for age and other independent variables found to be significantly associated with RLS status in the initial overall model. Histograms and frequency distributions of the dependent variables (e.g., definite RLS, no RLS, indeterminate) were constructed. Bivariate associations were examined using scatter plots, tabular methods, and analysis of variance as appropriate for the types of variables. Confounding was examined between our primary predictor (e.g., HIV status) and our covariates using correlations for continuous data and cross-tabulations for categorical data. To characterize sleep-related burden by HIV status, responses on sleep questionnaires and objective measures were compared between men with and without RLS. Measures of sleep-disordered breathing and periodic limb movements during sleep were compared among the groups. Similarly, actigraphy-measures of sleep timing, fragmentation, and nocturnal movements were also compared. Comparison statistics was per Student’s t-test for continuous data while Chi-square test was used for categorical data. Post-hoc tests were performed with Tukey’s test where significant differences between the four groups were detected. For all analyses, p < 0.05 was defined as statistically significant. Statistical analyses were performed with SPSS Statistics 25.0 (SPSS, Chicago, IL).

Results

Sample characteristics

The sample consisted of 942 middle-aged men (526 HIV positive, 416 HIV negative; 69% white) recruited from four clinical sites (Table 1). Twenty percent of the sample were current smokers, 7% met criteria for excessive alcohol use, and 11% reported daily use of marijuana or hash. Comorbidities were prevalent with 22% having hypertension and 25% reporting depressive symptoms. Laboratory-based criteria diagnoses of type 2 diabetes, chronic kidney disease, and anemia were met for 16%, 16%, and 10% of the cohort, respectively. Among men with HIV, the mean length of HIV infection was 27 ± 8 years with most using effective ART treatment with undetectable HIV viral load (75%) and CD4 counts above 500 (74%). Compared to men without HIV, men with HIV were significantly younger (54 ± 11 vs 60 ± 12 years, p < 0.001), more likely to be of racial minority background (37% vs 23%, p < 0.001), and more likely to be of Hispanic/Latino ethnicity (18% vs 7%, p < 0.001). Furthermore, men with HIV were significantly more likely to be current smokers (24% vs 14%, p < 0.001) and meet diagnostic criteria for anemia (13% vs 6%, p < 0.001) and chronic kidney disease (20% vs 12%, p < 0.001) than men without HIV. No other demographic, comorbidity, or medication use differences were noted between the groups.

Table 1

Comparison of men with and without HIV by characteristics.

Characteristic	All	HIV +	HIV -	p-value
	(n = 942)	(n = 526)	(n = 416)
Demographics
Age (yrs)	57 ± 12	54 ± 11	60 ± 12	<0.001
BMI (kg/m2)	27 ± 5	27 ± 5	28 ± 5	0.11
Race, n (%)				<0.001
White	652 (69)	332 (63)	320 (77)
Black	270 (29)	182 (35)	88 (21)
Other	20 (2)	12 (2)	8 (2)
Hispanic ethnicity, n (%)	125 (13)	95 (18)	30 (7)	<0.001
Recruitment site, n (%)				0.29
Baltimore	264 (28)	144 (27)	120 (29)
Chicago	199 (21)	123 (23)	76 (18)
Pittsburgh	230 (24)	123 (23)	107 (26)
Los Angeles	249 (26)	136 (26)	113 (27)
Health behaviors, n (%)
Current smoker	187 (20)	127 (24)	60 (14)	<0.001
Excessive alcohol use	70 (7)	33 (6)	37 (9)	0.14
Daily marijuana	100 (11)	59 (11)	41 (10)	0.52
Heroin/Opiates	32 (3)	22 (4)	10 (2)	0.13
Comorbidities, n (%)
Anemia	95 (10)	71 (13)	24 (6)	<0.001
Hypertension	204 (22)	98 (18)	106 (25)	0.01
Type 2 Diabetes	151 (16)	92 (17)	59 (14)	0.17
Chronic kidney disease	155 (16)	106 (20)	49 (12)	0.001
Depression	235 (25)	146 (28)	89 (21)	0.03
Medications, n (%)*
Anxiolytic/sedatives	180 (22)	98 (22)	82 (23)	0.87
Antidepressants	147 (18)	88 (20)	59 (16)	0.23
HIV variables
Disease duration (yrs)	-	27 ± 8	-
CD4 nadir (pre-treatment)	-	463 ± 244	-
CD4 count > 500, n (%)	-	387 (74)	-
Undetectable HIV viral load	-	394 (75)	-
ART treatment	-	509 (97)	-

Data presented as means ± SD or frequency (%). Group comparisons per Students t-test or Chi-square tests.

* The medication variable contained missing data with n = 802. BMI body mass index; ART, antiretroviral therapy.

Prevalence and correlates of RLS by HIV status

Fig 1 compares RLS prevalence by HIV status. The prevalence of “definite” RLS was similar among men with HIV (n = 48; 9.1%) and men without HIV (n = 36; 8.7%). However, the prevalence for the “indeterminate” category was higher among men with HIV relative to men without HIV (17.9% vs 12.0%, p = 0.039). Comparing RLS characteristics among those with “definite RLS”, men with HIV had similar age at onset of symptoms (48 ± 14 vs 47 ± 16 years; p = 0.79), levels of moderate to severe distress (63% vs 56%, p = 0.65), and frequency of RLS symptoms than men without HIV. Specifically, among men with HIV, 40% reported symptoms once weekly or less often, 31% reported symptoms 2–3 days weekly, and 29% reported symptoms 4 days or more weekly. A similar distribution of symptoms was observed among men without HIV with 31% reporting symptoms once weekly or less frequently, 36% reporting symptoms 2–3 times weekly, and 33% reporting symptoms at least 4 times weekly.

Fig 1

Unadjusted prevalence of RLS by HIV status.

Data represent RLS status prevalence with error bars.

To determine if HIV was associated with “definite” or “indeterminate” RLS status after adjusting for potential confounders, a multinomial logistic regression model was constructed. As shown in Table 2, HIV status was not associated with “indeterminate” or “definite” RLS in these models. The only factor significantly associated with “indeterminate” RLS status was current depressive symptoms (OR 1.68; 95% CI 1.07–2.65). In contrast, covariates significantly associated with “definite” RLS included white race (OR 2.20; 95% CI 1.10–4.38), anemia (OR 2.22; 95% CI 1.03–4.79), current depressive symptoms (OR 1.82; 95% CI 1.05–3.15), and active use of antidepressant medications (OR 2.03; 95% CI 1.13–3.64).

Table 2

Adjusted odds ratio for RLS status in men with and without HIV.

Variables	Indeterminate		Definite
	RLS (N = 117)		RLS (N = 74)
Demographics
Age	0.99	0.97–1.01	1.00	0.98–1.03
White race (ref non-white)	1.45	0.88–2.41	2.20	1.10–4.38 *
Health behaviors
Current smoker	1.21	0.71–2.07	0.99	0.49–2.00
Alcohol abuse	1.47	0.73–2.94	1.16	0.46–2.90
Daily marijuana	1.23	0.65–2.32	1.38	0.62–3.05
Heroin/Opiates	0.72	0.20–2.56	2.75	0.97–7.79
Comorbidities
HIV	1.52	0.98–2.35	1.25	0.73–2.13
Anemia	1.10	0.53–2.27	2.22	1.03–4.79 *
Hypertension	1.36	0.84–2.21	1.71	0.98–3.00
Diabetes	1.11	0.65–1.90	1.11	0.58–2.10
Chronic kidney disease	0.93	0.54–1.61	0.80	0.41–1.57
Depression	1.68	1.07–2.65 *	1.82	1.05–3.15 *
Medications
Anxiolytic/sedatives	1.02	0.61–1.69	0.92	0.50–1.71
Antidepressants	1.07	0.62–1.84	2.03	1.13–3.64 *

§Based on multivariable multinomial logistic regression results (referenced to “no RLS”; n = 587).

* p < 0.05, ** p < 0.01.

To examine whether HIV specific factors were associated with RLS status, a multinomial model was constructed in only those with HIV, sequentially adjusting for age and the significant covariates listed above. As shown in Table 3, none of the three characteristics examined (HIV duration, CD4 count > 500, or viral load suppression) was associated with “indeterminate” RLS. In contrast, HIV disease duration was associated with “definite” RLS (OR 1.08; 95% CI 1.01–1.16) in the fully adjusted model. To assess the potential effects of disease duration, HIV disease duration and RLS prevalence were cross-tabulated. No cases of “definite RLS” were reported by men who had HIV < 20 years while similar prevalence of RLS was reported by men with HIV between 20–30 years and > 30 years (10.1% vs 10.2%).

Table 3

Multinomial models of HIV specific predictors of RLS status in men with HIV.

HIV variable	Model A		Model B		Model C		Model D
	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI
Definite RLS (N = 47)
Disease duration (years)	1.05	1.01–1.10 *	1.05	0.99–1.12	1.06	1.00–1.13 *	1.08	1.02–1.16 *
CD4 count > 500	1.64	0.73–3.67	1.61	0.71–3.63	1.94	0.83–4.54	1.53	0.65–3.60
Undetectable viral load	1.70	0.33–3.95	1.61	0.69–3.78	1.59	0.67–3.77	1.75	0.69–4.45
Indeterminate RLS (N = 90)
Disease duration (yrs)	1.00	0.97–1.04	1.03	0.99–1.07	1.03	0.99–1.07	1.03	0.99–1.08
CD4 count > 500	0.76	0.45–1.28	0.69	0.41–1.19	0.70	0.43–1.20	0.64	0.36–1.15
Undetectable viral load	0.96	0.56–1.65	0.99	0.57–1.73	1.00	0.57–1.74	0.93	0.50–1.72

Multinomial logistic regression results (referenced to “no RLS”; n = 367).

Significance level is labeled as * p < 0.05, ** p < 0.01.

Model A: Unadjusted; Model B: demographics (age, race).

Model C: Model B + Comorbidities (anemia, depression).

Model D: Model C + medications (antidepressants).

Sleep-related burden comparisons across HIV and RLS categories

On sleep questionnaires, men with HIV and RLS reported significantly worse overall sleep quality than each of the three other groups (Table 4). In addition, they reported significantly longer latency to sleep onset and time in bed than men without RLS. Finally, they were significantly sleepier than HIV negative men without RLS when comparing the ESS as a continuous variable (9.0 ± 4.6 vs 7.1 ± 4.4, p = 0.04) or at a pathologic cut off value exceeding 10 (17% vs 35%, p = 0.01). However, there were no differences in prevalence or severity of sleep disordered breathing or oxygen nadir between the groups. Actigraphic data showed that men with HIV and RLS had longer wake after sleep onset time (69 ± 30 mins vs 53 ± 26 mins, p = 0.001), lower sleep efficiency (83 ± 7% vs 87 ± 6%, p < 0.001), and greater mean nocturnal movements (22 ± 11 vs 16 ± 9, p < 0.001) than men without HIV and without RLS. The fragmentation index of men with HIV and RLS was also significantly higher than that of HIV negative men with or without RLS. Furthermore, men with HIV without RLS had significantly longer sleep onset latency, greater wake after sleep onset time, and poor sleep efficiency than men without HIV and without RLS.

Table 4

Comparison of sleep parameters by HIV and RLS status.

Characteristic	No RLS and HIV-	RLS and HIV-	No RLS and HIV +	RLS and HIV +	p-value
	(N = 330)	(N = 36)	(N = 384)	(N = 48)
PSQI
Total score	6.0 ± 3.4	7.2 ± 3.3	6.8 ± 3.6 d	9.3 ± 4.6 a	<0.001
SOL, mins	23 ± 35	33 ± 38	26 ± 27	42 ± 48 b,c	0.002
Sleep duration, hrs	6.7 ± 1.4	7.0 ± 1.1	6.7 ± 1.3	6.8 ± 2.4	0.66
Time in bed, hrs	7.7 ± 1.2	8.1 ± 1.3	7.7 ± 1.8	8.6 ± 2.7 b,c	0.002
Epworth sleepiness scale	7.1 ± 4.4	7.9 ± 3.9	7.3 ± 4.6	9.0 ± 4.6 c	0.04
Excessive sleepiness(%) (ESS >10)	17	31	22	35	0.01
Polysomnography
Total sleep time, mins	384 ± 84	384 ± 98	370 ± 88	354 ± 91	0.06
AHI (events/hr)	21 ± 18	22 ± 16	19 ± 16	22 ± 19	0.28
OSA diagnosis (%)	87	90	84	87	0.68
Oxygen nadir	83 ± 7	82 ± 7	83 ± 6	83 ± 8	0.86
PLMS index	5 ± 14	10 ± 16	5 ± 12	8 ± 15	0.07
Actigraphy
Sleep duration, mins	412 ± 70	432 ± 63	405 ± 78	409 ± 75	0.21
SOL, mins	10 ± 9	10 ± 8	13 ± 13 d	12 ± 9	0.009
WASO, mins	53 ± 26	58 ± 29	60 ± 29 d	69 ± 30 c	0.001
Sleep efficiency, (%)	87 ± 6	87 ± 6	85 ± 7 d	83 ± 7 c	<0.001
Fragmentation index	24 ± 9	25 ± 9	26 ± 10	30 ± 10 b,c	<0.001
Mean activity (count/min)	16 ± 9	18 ± 11	19 ± 11 d	22 ± 11 c	<0.001

Data presented as means ± SD or frequency (%). Group comparisons per ANOVA or Chi-square tests. PSQI Pittsburgh sleep quality index; SOL, sleep onset latency; WASO wake after sleep onset; AHI apnea-hypopnea index; OSA, obstructive sleep apnea; PLMS periodic limb movements in sleep.

Post-hoc significance levels are labeled as follows

ap<0.05 for comparison between HIV+/ RLS and each of the other groups

bp<0.05 for comparison between HIV+/RLS and HIV+/No RLS

cp<0.05 for comparison between HIV+/RLS and HIV-/No RLS

dp<0.05 for comparisons between HIV-/No RLS and HIV+/No RLS.

Discussion

In this cross-sectional analysis of the sleep data collected in the MACS cohort, the prevalence of RLS among men with HIV was similar to that of men without HIV. Both of these estimates fall within the RLS prevalence estimates reported for the US general population (2.5–16.0%) [1, 5, 7] and are consistent with that reported in other HIV cohorts. Employing validated questionnaire-based assessment of RLS, two prior studies have reported that the prevalence of RLS was equivalent among PLHIV and those without HIV [11, 12]. In a multisite study from the United Kingdom (N = 483; 88% White), Kunisaki et al reported the prevalence of multiple sleep disorders including RLS in older and younger individuals with HIV [12]. Older people with a median age of 60 years and HIV had a RLS prevalence of 15.5%, which was similar to the prevalence reported in the older group (14.4%) without HIV. In contrast, young participants with a median age of 46 years and HIV had a RLS prevalence of only 7.8%. Similarly, a study conducted in United States with a more diverse sample (N = 316; 41% White) also found that the prevalence of RLS was similar in people with and without HIV (11% vs 8%, p = 0.80) [11]. In contrast, a single center study (N = 228) from Germany found that the prevalence of RLS was significantly higher in people without HIV (33% vs 7%, p < 0.001) [8]. The differences across previous reports may represent differences in study sample characteristics and the methodology used for assessing RLS. The data provided here adds to the existing knowledge base about RLS in HIV by using a larger, multicenter, racially diverse cohort and examining the association of pertinent objectively-verified comorbidities, health behaviors and medications.

Although HIV status itself was not associated with RLS in adjusted analyses, several previously described demographic and medical comorbid associations were detected [1, 5, 9]. White men were twice as likely to fulfill RLS diagnostic criteria as men of minority background. These data are consistent with adjusted analyses of the Multi-Ethnic Study of Atherosclerosis where Black individuals had a lower likelihood (OR 0.56; 95% CI 0.32–0.96) of RLS with periodic limb movements as Whites [24]. Prevalence of RLS is known to be higher among individuals of Northern European background associated with genetic predisposition [7]. Anemia was also associated with RLS given the important role of iron as a cofactor for tyrosine hydroxylase, which converts tyrosine to L-DOPA, a dopamine precursor [25]. Low peripheral iron (serum ferritin) and central nervous system stores have been associated with dopamine dysfunction and RLS severity [26-28]. Depression has been recognized to have a bidirectional relationship with RLS and recent studies have suggested that sleep disruption may partially mediate this association [29]. In a cross-sectional analysis of the Osteoporotic Fractures of Older Men study, the association between RLS severity and depressive symptoms was attenuated the most by adjusting for sleep efficiency. These data suggest that sleep onset insomnia caused by the uncomfortable sensation or sleep fragmentation caused by nocturnal periodic limb movements may precipitate depressive symptoms (e.g., fatigue, cognitive deficits). Finally, several anti-depressants (e.g., mirtazapine, venlafaxine) have also been reported to worsen or precipitate RLS by enhancing serotonergic transmission [30]. Thus, health care providers should consider these RLS risk factors when assessing PLHIV with insomnia symptoms.

A unique finding of the current study is that among men with HIV an association was noted between HIV duration and RLS. This association was independent of age, a known predictor of RLS [1]. Interestingly, all RLS cases were detectable among men with HIV duration of more than 20 years. Recently, age-related changes in the periodicity of PLMS have been reported in individuals with RLS, stabilizing during middle age but increasing after the age of 60 [31]. Whether such age-related phenomena also occur in older people with HIV is currently unknown but merits future study. Also, it is unclear if HIV-associated neurodegeneration in CNS sensory-motor modulating areas linked to RLS symptomatology (e.g., basal ganglia, substantia nigra) may potentially explain this association [26–30, 32]. As HIV may remain latent in microglia and macrophages, accelerated brain atrophy and active CNS inflammatory processes have been reported even among individuals with undetectable HIV viral load [33, 34]. Thus, a longer duration of HIV may also be associated with a chronic CNS inflammation, CNS iron deficiency, and loss of myelin integrity [27]. Recently, Hennessy et al described a higher risk of RLS among people with HIV carrying alleles for proteins regulating iron transport from glial cells and pro-inflammatory cytokine IL-17 [11]. In agreement with the data presented, some studies among people with HIV have failed to find associations between CD4 count, viral load count, ART therapy and RLS. However, Happe et al did report that CD4 count was inversely associated with RLS severity [10]. The men in MACS had been living with HIV for much longer (27 ± 12 years) than individuals in other HIV-RLS studies (e.g., Hennessy et al: 12 ± 7 years) [9]. Thus, there are numerous study specific differences which may account for these disparate associations.

This study describes for the first time the objective sleep-related burden of RLS among men with and without HIV. Men with HIV and RLS had greater sleep onset insomnia complaints, showed poorer sleep quality, greater sleepiness, and fragmented sleep than men without HIV/RLS. Unlike many other studies in RLS, our study sample included individuals with RLS and other comorbid sleep disorders. Thus, some of the differences we detected between men with HIV and men without HIV/RLS may not be due to RLS alone. For example, although men with HIV and RLS and men without HIV/RLS had equivalent severity of OSA (i.e., AHI, oxygen nadir), it is possible that this sleep disorder may account for some of the groups’ differences in levels of daytime sleepiness. A diagnosis of sleep apnea was very common across all groups indicating that multiple sleep disorders may co-exist in people with HIV and that their impact may be cumulative. For example, Kunisaki et al reported that among people with HIV, as the number of sleep disorders increased, physical, mental, and sleep-related quality of life scores worsened [12]. Furthermore, behavioral factors counterproductive to sleep consolidation (i.e., spending excessive time in bed) were more common in men with HIV and RLS than in men without RLS. This finding may seem unusual for individuals with RLS alone as laying still in bed may activate RLS symptoms [1, 2]. However, many patients with RLS may develop comorbid insomnia, dysfunctional sleep beliefs, and engage in deleterious behaviors mimicking those of chronic insomnia sufferers (e.g., getting into bed earlier). By addressing behavioral targets and sleep cognitions, cognitive behavioral therapy for insomnia has been shown to be superior to sleep hygiene in improving insomnia, sleep quality, and sleep efficiency in people with RLS and comorbid insomnia [35]. As insomnia disorder is the most common sleep problem reported, it is of clinical value to screen PLHIV for RLS [12, 36]. Although there were several statistically significant differences in some sleep metrics detected between men without RLS by HIV status, these were smaller and likely of little clinical significance. These data show that sleep disorders are a prevalent comorbidity in HIV and represent treatment opportunities to enhance quality of life in people with HIV.

Limitations

The current study has several important limitations. The diagnosis of RLS was established by questionnaire and did not include a clinical assessment. Although the CH-RLSq instrument we used to assess RLS is based on the diagnostic criteria, it does not provide accepted RLS diagnostic categories (i.e., indeterminate) [16]. However, these RLS categories were utilized for comparative future studies utilizing this instrument. Another major limitation of the instrument is that it does not provide an RLS severity measure akin to the international RLS study group severity rating scale [37]. Thus, it is unclear from these data if the RLS severity of men with HIV differs from that of men without HIV. Furthermore, our RLS prevalence may be underestimated by the absence of women, who have a greater prevalence of the disorder [8]. Additionally, adjustment for others lifestyle factors (e.g., stress, physical activity), nutritional deficiencies (e.g., vitamin B12), and medications (e.g., thyroxine, dopamine-blocking medications) which may impact RLS presentation was not possible [1, 8, 9]. Some association reported with RLS, although not reaching statistical significance, did have wide confidence intervals. Therefore, it is possible that other clinically important factors may be associated with RLS in HIV, which this study was under powered to detect. Finally, the method by which participants were included into the sleep ancillary protocol of the MACS may have introduced some bias.

Conclusions

In conclusion, although the prevalence of RLS was not higher among men with HIV, it is an important diagnosis to consider among people presenting with insomnia complaints and among people with long-standing HIV. As sleep disorders are treatable and may often coexist, familiarity with the cardinal RLS symptoms and its risk factors may enhance comprehensive HIV care.

19 Aug 2021

PONE-D-21-23631

Prevalence and Correlates of Restless Legs Syndrome in Men Living with HIV

PLOS ONE

Dear Dr. Wallace,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please note that one of the most important point, indicated by both reviewers, is that of the definition of RLS "severity"; in particular, explain if the validated IRLS scale was used or not. In the first case, it would be a strenght of the study, in the second, a very important limitations to be declared and discussed.

Please submit your revised manuscript by Oct 03 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Raffaele Ferri

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

3. Thank you for stating the following financial disclosure:

"The contents of this publication are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health (NIH). MWCCS (Principal Investigators): Atlanta CRS (Ighovwerha Ofotokun, Anandi Sheth, and Gina Wingood), U01-HL146241; Baltimore CRS (Todd Brown and Joseph Margolick), U01-HL146201; Bronx CRS (Kathryn Anastos and Anjali Sharma), U01-HL146204; Brooklyn CRS (Deborah Gustafson and Tracey Wilson), U01-HL146202; Data Analysis and Coordination Center (Gypsyamber D’Souza, Stephen Gange and Elizabeth Golub), U01-HL146193; Chicago-Cook County CRS (Mardge Cohen and Audrey French), U01-HL146245; Chicago-Northwestern CRS (Steven Wolinsky), U01-HL146240; Northern California CRS (Bradley Aouizerat, Jennifer Price, and Phyllis Tien), U01-HL146242; Los Angeles CRS (Roger Detels and Matthew Mimiaga), U01-HL146333; Metropolitan Washington CRS (Seble Kassaye and Daniel Merenstein), U01-HL146205; Miami CRS (Maria Alcaide, Margaret Fischl, and Deborah Jones), U01-HL146203; Pittsburgh CRS (Jeremy Martinson and Charles Rinaldo), U01-HL146208; UAB-MS CRS (Mirjam-Colette Kempf, Jodie Dionne-Odom, and Deborah Konkle-Parker), U01-HL146192; UNC CRS (Adaora Adimora), U01-HL146194. The MWCCS is funded primarily by the National Heart, Lung, and Blood Institute (NHLBI), with additional co-funding from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD), National Institute On Aging (NIA), National Institute Of Dental & Craniofacial Research (NIDCR), National Institute Of Allergy And Infectious Diseases (NIAID), National Institute Of Neurological Disorders And Stroke (NINDS), National Institute Of Mental Health (NIMH), National Institute On Drug Abuse (NIDA), National Institute Of Nursing Research (NINR), National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Minority Health and Health Disparities (NIMHD), and in coordination and alignment with the research priorities of the National Institutes of Health, Office of AIDS Research (OAR). MWCCS data collection is also supported by UL1-TR000004 (UCSF CTSA), UL1-TR003098 (JHU ICTR), UL1-TR001881 (UCLA CTSI), P30-AI-050409 (Atlanta CFAR), P30-AI-073961 (Miami CFAR), P30-AI-050410 (UNC CFAR), P30-AI-027767 (UAB CFAR), and P30-MH-116867 (Miami CHARM)."

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

4. Thank you for stating the following in your Competing Interests section:

"No"

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state "The authors have declared that no competing interests exist.", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now

This information should be included in your cover letter; we will change the online submission form on your behalf

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Very interesting manuscript, for the first time the prevalence of RLS in patients with HIV is evaluated, on a very large sample, although (as pointed out by the authors) conducting the survey only on men represents a major limitation of the study, being RLS, as well as several immunological pathologies, more frequent in women. I believe that the authors used an excellent methodology, however, several clarifications are necessary, especially concerning the international diagnostic criteria of RLS and the disorders often related to it (PLMS), so I believe the following changes should be made:

1. On line 82 page 4 authors should refer to the international diagnostic criteria for RLS (Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, Zucconi M, Ferri R, Trenkwalder C, Lee HB; International Restless Legs Syndrome Study Group. Restless legs syndrome / Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria - history, rationale, description, and significance. Sleep Med. 2014 Aug; 15 (8): 860-73. Doi: 10.1016 / j.sleep.2014.03.025. Epub 2014 May 17. PMID: 25023924)

2. On line 85 page 4 authors should refer to the international diagnostic criteria for periodic movements of the lower limbs in sleep (Ferri R, Fulda S, Allen RP, Zucconi M, Bruni O, Chokroverty S, Ferini-Strambi L, Frauscher B, Garcia-Borreguero D, Hirshkowitz M, Högl B, Inoue Y, Jahangir A, Manconi M, Marcus CL, Picchietti DL, Plazzi G, Winkelman JW, Zak RS; International and European Restless Legs Syndrome Study Groups (IRLSSG and EURLSSG) . World Association of Sleep Medicine (WASM) 2016 standards for recording and scoring leg movements in polysomnograms developed by a joint task force from the International and the European Restless Legs Syndrome Study Groups (IRLSSG and EURLSSG). Sleep Med. 2016 Oct; 26: 86-95. Doi: 10.1016 / j.sleep.2016.10.010. Epub 2016 Nov 7. PMID: 27890390).

3. Line 146 page 6: it is advisable to specify the cutoff values of the ESS scale to be considered pathological.

4. Line 155 page 7: the international diagnostic criteria for PLMS must be indicated in the bibliographic notes (already indicated in point 2), then replace in the bibliographic note 17.

5. Line 255 page 12: the authors speak of "definite or indeterminate RLS", a denomination that however does not exist in the diagnostic criteria and in the definition of the pathology.

6. Line 358 page 17: Add as another limitation of the study the fact that the authors did not also consider the severity of RLS, for example by means of the international Restless Legs Syndrome study group severity rating scale:

a. Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, Trenkwalder C. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. The International Restless Legs Syndrome Study Group. Sleep Med. 2003 Mar;4(2):121-32

b. Sharon D, Allen RP, Martinez-Martin P, Walters AS, Ferini Strambi L, Högl B, Trotti LM, Buchfuhrer M, Swieca J, Bogan RK, Zak R, Hensley JG, Schaefer LA, Marelli S, Zucconi M, Stefani A, Holzknecht E, Olvera V, Meaklim H , Laska I, Becker PM; International RLS Study Group. Validation of the self-administered version of the international Restless Legs Syndrome study group severity rating scale - The sIRLS. Sleep Med. 2019 Feb; 54: 94-100. Doi: 10.1016 / j.sleep.2018.10.014. Epub 2018 Oct 29. PMID: 30529783.), another important feature to evaluate, besides the duration of illness.

7. Line 360 page 17: add that also the distribution of PLMS varies with age in patients with RLS (Ferri R, DelRosso LM, Silvani A, Cosentino FII, Picchietti DL, Mogavero P, Manconi M, Bruni O. Peculiar lifespan changes of periodic leg movements during sleep in restless legs syndrome. J Sleep Res. 2020 Jun; 29 (3): e12896. doi: 10.1111 / jsr.12896. Epub 2019 Jul 16. PMID: 31313413) and therefore it would be interesting to evaluate this aspect in patients with HIV, also in the light of what is described in the discussion also on PLMS.

Reviewer #2: In the paper “Prevalence and correlates of Restless Legs Syndrome in men living with HIV” the authors aim to determine the prevalence of RLS, associated clinical correlates, and characterize sleep-related differences in men with and without HIV. They included 942 men from the Multicenter AIDS Cohort 107 Study (MACS). The prevalence of definite RLS was comparable in men with and without HIV. White race, anemia, depression, and antidepressant use were each independently associated with RLS. HIV disease duration was also associated with RLS. Men with HIV and RLS reported poorer sleep quality, greater sleepiness, and had worse objective sleep efficiency/fragmentation than men without HIV/RLS. The study describes RLS features among men with and without HIV, although some limitations described by the authors themselves are present. Indeed, to be included in this analysis, participants had to complete the sleep questionnaires, overnight polysomnography, and actigraphy.

It could be interesting to know if RLS symptoms were chronic or intermittent adding informations on the frequency of RLS symptoms in patients with and without HIV.

The authors found an interesting correlation between HIV disease duration and RLS. In these cases, has the patients been diagnosed before the study and asking for treatment?

In the discussion session the authors reported increased RLS severity in patients with HIV in comparison with patients without HIV. What does it mean “severity” if any RLS severity scale has not been included in the study?

Men with HIV and RLS had greater sleepiness, but once again the lack of excessive daytime time sleepiness is a supportive criteria for RLS diagnosis. The authors reported that sleep apnea was very common across all groups indicating that multiple sleep disorders may co-exist in people with HIV and that their impact may be cumulative. This aspect is interesting but it should be distinguished the impact of other sleep disorders from the impact of RLS itself.

Finally, I suggest to discuss some unexpected findings. For example, the authors reported a longer time in bed among patients with RLS. That is really strange because bed is usually the worst place for the onset of RLS symptoms.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

6 Sep 2021

09-04-2021

Dear Dr Ferri:

We thank you and the reviewers of our manuscript for the thoughtful feedback. Please find enclosed a point-by-point rebuttal to the reviewers’ comments.

Reviewer 1

1. On line 82 page 4 authors should refer to the international diagnostic criteria for RLS (Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, Zucconi M, Ferri R, Trenkwalder C, Lee HB; International Restless Legs Syndrome Study Group. Restless legs syndrome / Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria - history, rationale, description, and significance. Sleep Med. 2014 Aug; 15 (8): 860-73. Doi: 10.1016 / j.sleep.2014.03.025. Epub 2014 May 17. PMID: 25023924)

This reference has been added as suggested.

2. On line 85 page 4 authors should refer to the international diagnostic criteria for periodic movements of the lower limbs in sleep (Ferri R, Fulda S, Allen RP, Zucconi M, Bruni O, Chokroverty S, Ferini-Strambi L, Frauscher B, Garcia-Borreguero D, Hirshkowitz M, Högl B, Inoue Y, Jahangir A, Manconi M, Marcus CL, Picchietti DL, Plazzi G, Winkelman JW, Zak RS; International and European Restless Legs Syndrome Study Groups (IRLSSG and EURLSSG) . World Association of Sleep Medicine (WASM) 2016 standards for recording and scoring leg movements in polysomnograms developed by a joint task force from the International and the European Restless Legs Syndrome Study Groups (IRLSSG and EURLSSG). Sleep Med. 2016 Oct; 26: 86-95. Doi: 10.1016 / j.sleep.2016.10.010. Epub 2016 Nov 7. PMID: 27890390).

This reference has been added as suggested.

3. Line 146 page 6: it is advisable to specify the cutoff values of the ESS scale to be considered pathological.

This detail (ESS > 10) has been added in the Methods section as suggested. This metric has also been added to Table 4.

4. Line 155 page 7: the international diagnostic criteria for PLMS must be indicated in the bibliographic notes (already indicated in point 2), then replace in the bibliographic note 17.

This has been changed as suggested.

5. Line 255 page 12: the authors speak of "definite or indeterminate RLS", a denomination that however does not exist in the diagnostic criteria and in the definition of the pathology.

We have clarified that this RLS terminology is per the developer of the questionnaire and does not exist in the RLS diagnostic criteria. This has been explicated fully in the Methods and Limitations sections. However, we specifically retained this terminology because we solely utilized this questionnaire to determine the RLS categories. We have removed the language concerning RLS “diagnostic categories” to read RLS “categories”

6. Line 358 page 17: Add as another limitation of the study the fact that the authors did not also consider the severity of RLS, for example by means of the international Restless Legs Syndrome study group severity rating scale:

a. Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, Trenkwalder C. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. The International Restless Legs Syndrome Study Group. Sleep Med. 2003 Mar;4(2):121-32.

We have added this to the Limitations subsection of the Discussion and added references as suggested.

7. Line 360 page 17: add that also the distribution of PLMS varies with age in patients with RLS (Ferri R, DelRosso LM, Silvani A, Cosentino FII, Picchietti DL, Mogavero P, Manconi M, Bruni O. Peculiar lifespan changes of periodic leg movements during sleep in restless legs syndrome. J Sleep Res. 2020 Jun; 29 (3): e12896. doi: 10.1111 / jsr.12896. Epub 2019 Jul 16. PMID: 31313413) and therefore it would be interesting to evaluate this aspect in patients with HIV, also in the light of what is described in the discussion also on PLMS.

We have added this interesting point to the discussion and highlighted this potential future aim.

Reviewer 2

1. It could be interesting to know if RLS symptoms were chronic or intermittent adding informations on the frequency of RLS symptoms in patients with and without HIV.

One of the items of the CH-RLSq queries RLS symptom frequency over the last 12 months. We have added details about the response pattern to this item to the results section.

2. The authors found an interesting correlation between HIV disease duration and RLS. In these cases, has the patients been diagnosed before the study and asking for treatment?

There was no information collected during the MACS sleep ancillary study on whether individuals had a pre-existing diagnosis of RLS. The medication categories collected were broad (i.e., antidepressant, tranquilizers) making the adjustment for more RLS-specific (e.g., dopamine agonists) medications was not possible.

3. In the discussion session the authors reported increased RLS severity in patients with HIV in comparison with patients without HIV. What does it mean “severity” if any RLS severity scale has not been included in the study?

We have removed mention of “severity” of RLS throughout the manuscript. As has been correctly pointed out, the score of the CH-RLSq cannot be inferred to mean greater RLS severity. The lack of severity assessment of the CH-RLSq has been added as a major limitation of the instrument in the Limitations subsection of the Discussion.

4. Men with HIV and RLS had greater sleepiness, but once again the lack of excessive daytime time sleepiness is a supportive criteria for RLS diagnosis. The authors reported that sleep apnea was very common across all groups indicating that multiple sleep disorders may co-exist in people with HIV and that their impact may be cumulative. This aspect is interesting but it should be distinguished the impact of other sleep disorders from the impact of RLS itself.

The reviewer is correct in pointing out that most patient with RLS patients may not report excessive daytime sleepiness (reference). In fact, Table 4 now shows that 31% of men without HIV and RLS and 35% of men with HIV and RLS had pathologic levels of daytime sleepiness (ESS > 10). However, an important difference between our study and many studies exploring daytime sleepiness in RLS is that most have exclude individuals with comorbid sleep disorders (Kallweit U et al 2009; Fulda S et al 2007). Therefore, some of the sleepiness may originate from these other comorbid sleep issues or other comorbidities that may be associated with hypersomnia and RLS (i.e., depressive symptoms). We have highlighted this important difference in our sample in the Discussion.

5. Finally, I suggest to discuss some unexpected findings. For example, the authors reported a longer time in bed among patients with RLS. That is really strange because bed is usually the worst place for the onset of RLS symptoms.

This is a good suggestion for clarification. Many patients with RLS have comorbid insomnia and engage in behaviors that further impact their sleep adversely. By targeting these behavioral targets, a recent RCT showed the superiority of cognitive behavioral therapy for insomnia over sleep hygiene in improving sleep quality, efficiency, and insomnia symptoms in patients with RLS and comorbid insomnia (Song ML et al Sleep Med 2020 Oct;74:227-234). We have added this reference and point to the discussion.

Once again, thank you for the gracious comments. We believe these changes have strengthened the manuscript considerably.

Sincerely,

Douglas Wallace and colleagues.

Submitted filename: ResponsetoReviewers_082921.docx

Click here for additional data file.

20 Sep 2021

Prevalence and correlates of restless legs syndrome in men living with HIV

PONE-D-21-23631R1

Dear Dr. Wallace,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Raffaele Ferri

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: The authors have adequately addressed all commnents including some changes throughout the text. The data support the conclusions

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

23 Sep 2021

PONE-D-21-23631R1

Prevalence and correlates of restless legs syndrome in men living with HIV

Dear Dr. Wallace:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Raffaele Ferri

Academic Editor

PLOS ONE